Paradigm Biocapital Advisors LP Y M Abs Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.62 Billion
- Q4 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,236,346 shares of YMAB stock, worth $24.2 Million. This represents 1.27% of its overall portfolio holdings.
Number of Shares
4,236,346
Previous 4,086,346
3.67%
Holding current value
$24.2 Million
Previous $53.7 Million
38.18%
% of portfolio
1.27%
Previous 1.93%
Shares
4 transactions
Others Institutions Holding YMAB
# of Institutions
113Shares Held
26.9MCall Options Held
5.6KPut Options Held
900-
Black Rock Inc. New York, NY2.94MShares$16.8 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.86MShares$16.4 Million12.11% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$12.6 Million1.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA2MShares$11.4 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$10.5 Million0.09% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $250M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...